Safety and Efficacy of Yttrium-90-Labeled Anti-CD45 Antibody (90Y-DOTA-BC8) Followed By a Standard Reduced-Intensity Hematopoietic Stem Cell Transplant (HCT) Regimen for Patients with Refractory/Relapsed Leukemia or High-Risk Myelodysplastic Syndrome (MDS)
Phuong Vo,Ted Gooley,Joseph G. Rajendran,Darrell R. Fisher,Johnnie J. Orozco,Damian J. Green,Ajay K. Gopal,Robyn L. Haaf,Margaret E. Nartea,Rainer Storb,Frederick R. Appelbaum,Oliver W. Press,John M. Pagel,Brenda M. Sandmaier
出处
期刊:Blood [American Society of Hematology] 日期:2018-11-29卷期号:132 (Supplement 1): 1018-1018被引量:8